StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences gross margin

Gross margin is gross profit as a percentage of revenue.

Pacira BioSciences's gross margin for the twelve months ending Jun 30, 2026 was 79.2%. For fiscal 2025 it was 79.4%, against 75.7% the year before. The highest annual figure on record is 79.4% in fiscal 2025.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202579.4%+3.7
FY2024Dec 31, 202475.7%+3.0
FY2023Dec 31, 202372.6%+2.5
FY2022Dec 31, 202270.1%−4.0
FY2021Dec 31, 202174.1%+1.4
FY2020Dec 31, 202072.7%−2.0
FY2019Dec 31, 201974.7%+0.4
FY2018Dec 31, 201874.3%+4.9
FY2017Dec 31, 201769.3%+9.2
FY2016Dec 31, 201660.2%−11.0
FY2015Dec 31, 201571.1%+10.3
FY2014Dec 31, 201460.8%+24.8
FY2013Dec 31, 201336.0%+18.2
FY2012Dec 31, 201217.8%+24.5
FY2011Dec 31, 2011-6.7%−22.4
FY2010Dec 31, 201015.7%−2.3
FY2009Dec 31, 200918.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202677.0%−0.4
Q1 FY2026Mar 31, 202679.5%−0.2
Q4 FY2025Dec 31, 202579.5%+0.8
Q3 FY2025Sep 30, 202580.9%+4.0
Q2 FY2025Jun 30, 202577.4%+2.3
Q1 FY2025Mar 31, 202579.7%+8.1
Q4 FY2024Dec 31, 202478.7%+5.0
Q3 FY2024Sep 30, 202476.9%+1.2
Q2 FY2024Jun 30, 202475.1%+3.6
Q1 FY2024Mar 31, 202471.6%+2.2
Q4 FY2023Dec 31, 202373.7%+9.7
Q3 FY2023Sep 30, 202375.8%+6.0
Q2 FY2023Jun 30, 202371.6%+1.4
Q1 FY2023Mar 31, 202369.4%−7.7
Q4 FY2022Dec 31, 202264.0%−11.5
Q3 FY2022Sep 30, 202269.7%−3.1
Q2 FY2022Jun 30, 202270.1%−3.9
Q1 FY2022Mar 31, 202277.2%+3.5
Q4 FY2021Dec 31, 202175.5%+2.4
Q3 FY2021Sep 30, 202172.9%−1.6
Q2 FY2021Jun 30, 202174.0%+3.5
Q1 FY2021Mar 31, 202173.7%+1.8
Q4 FY2020Dec 31, 202073.0%−0.9
Q3 FY2020Sep 30, 202074.5%−4.2
Q2 FY2020Jun 30, 202070.5%−5.0
Q1 FY2020Mar 31, 202071.9%+1.8
Q4 FY2019Dec 31, 201973.9%−0.8
Q3 FY2019Sep 30, 201978.7%+1.5
Q2 FY2019Jun 30, 201975.4%+0.3
Q1 FY2019Mar 31, 201970.1%+0.8
Q4 FY2018Dec 31, 201874.8%+1.7
Q3 FY2018Sep 30, 201877.2%+4.2
Q2 FY2018Jun 30, 201875.1%+8.7
Q1 FY2018Mar 31, 201869.3%+4.8
Q4 FY2017Dec 31, 201773.1%+5.5
Q3 FY2017Sep 30, 201772.9%+36.1
Q2 FY2017Jun 30, 201766.4%–
Q1 FY2017Mar 31, 201764.5%–
Q4 FY2016Dec 31, 201667.6%–
Q3 FY2016Sep 30, 201636.9%–

More Pacira BioSciences figures

See a number that looks wrong?